Regeneron : Phase 3 Trial Of Dupixent On Atopic Dermatitis Meets Primary And Secondary Endpoints
30/8 07:18
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) said Monday that a pivotal phase 3 trial, which evaluated Dupixent or dupilumab to treat moderate-to-severe atopic dermatitis in children aged 6 months to 5 years, met its primary and all secondary endpoint...